Comprehensive health policy improves access to TMS therapy for adolescents and adults

BlueCross BlueShield of North Carolina and Louisiana Medicaid Expand Coverage for Patients with Depression

MALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing and commercializing products that improve the quality of life for patients suffering from neurological disorders, announced that supplemental payers have updated their transcranial magnetic stimulation (TMS) coverage to lower barriers to access for patients with major depressive disorder (MDD). This expanded access allows people to receive a treatment, such as the company’s NeuroStar TMS therapy, earlier in their treatment regimen.

Effective immediately, BlueCross BlueShield (BCBS) of North Carolina has expanded its TMS policy to cover adolescents ages 15 and older, based on recent U.S. Food and Drug Administration (FDA) approval of NeuroStar as the first and only TMS treatment authorized for this population. BCBS of North Carolina’s policy covers more than 2.2 million insured lives. Additionally, effective immediately, Louisiana Medicaid has begun covering TMS for adults ages 18 and older. This is the first TMS coverage policy under Louisiana Medicaid, which has a footprint of more than 1.6 million insured lives.